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Delirium is an acute onset, fluctuant, confusional state with cognitive, emotional, 
perceptual, psychomotor, and sleep–wake cycle disturbances. It is often worse in the 
evening and at night, particularly with underlying dementia 1. Delirium is often not 
diagnosed due to fluctuating signs and symptoms. The most common clinical 
subtype in palliative care is hypoactive delirium, with reduced psychomotor activity 2. 
Delirium is especially common in palliative care, almost ubiquitous towards the end 
of life; up to 88% of patients develop delirium in the last weeks to hours of life 3.  
 
Older age and dementia are major risk factors. Current and projected demographic 
changes, with an increased elderly population, signal a need for physicians to have a 
better awareness of delirium diagnosis and assessment. A high level of suspicion 
and multidisciplinary team involvement is needed in diagnosis and management.  
 
The primary management is rapid diagnosis, as mortality increases with delay. This 
includes history (importantly collateral histories from carers, family, and staff), 
examination, and appropriate investigation (according to goals of care). The aim is to 
make the diagnosis and if possible confirm the cause(s). It is also important to 
determine the impact on the patient and family/carer and ascertain their needs.  
 
Delirium screening and diagnostic tools can help improve diagnosis but seldom used 
4. Clinicians should use low burden validated screening tools including the Single 
Question in Delirium (SQiD), Nursing Delirium Screening Scale (Nu-DESC), Delirium 
Observation Screening (DOS) Scale, and the Confusion Assessment Method (CAM) 
2. The CAM needs proper training. The 4AT assesses cognition (specifically 
attention) and is popular in elderly medicine. Currently, it has not been formally 
validated in palliative care patients but has been used in a hospice setting 5. 
Diagnostic criteria appear in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-5 and International Classification of Diseases (ICD)-11. 
Assessment tools (to confirm diagnosis and rate severity) include the Delirium Rating 
Scale revised-98 (DRS-R-98) and Memorial Delirium Assessment Scale (MDAS) 1. 
 
Identify and reverse underlying cause(s) of delirium if appropriate/consistent with 
goals of care and illness trajectory. The cause is often multifactorial, with usually one 
to six causes (median three) per episode 6. This is central to management and 
should be a key part of assessment post-diagnosis. Up to 50% of delirium episodes 
in palliative care have a cause which can be found and treated 6. If identified and the 
patient responds to appropriate treatment, this is the best approach.  
 
Common causes include dehydration; drug/alcohol withdrawal; electrolyte 
abnormalities (hypercalcaemia, inappropriate antidiuretic hormone secretion 
(SIADH), abnormal glucose); infection; and metabolic encephalopathy from hepatic, 
renal, heart or respiratory failure 1.  
Communication, education, information, and patient support (reassurance and 
support when not lucid and education when they are) are vital as delirium can be 
very distressing 2. In addition, education and support to family and staff will be 
needed. Furthermore, family/informal carers often support the patient and can help 
with non-pharmacological management.  
 
Non-pharmacological management is the mainstay of treatment for most episodes 
and needs frequent reinforcement (Box 1) 1 7. Non-pharmacological interventions are 
effective in older people 7 8 but still under evaluation in palliative care. In addition, 
avoid physical restraints and unnecessary urinary catheterisation. 
 
Box 1: Non-pharmacological delirium management 1 7. 
Correction of predisposing conditions (hearing, vision) 
Encourage mobilisation 
Improve sleep–wake patterns (day: exposure to daylight, discourage naps; evening: 
non-caffeinated drinks, relaxing music, minimise light, noise, disruptions) 
Orientation activities (explain where the patient is, who they are, who you are and 
your role, use orientation board, visible clock, and cognitive stimulation activities, e.g. 
Reminiscence) 
Minimise room changes  
Encourage and assist patients to drink (and eat) - provided they can swallow safely 
 
There have been two recent randomised controlled trials of pharmacological 
management in adult palliative care inpatients. One compared dose-titrated 
haloperidol and risperidone with placebo over three days in a multisite trial 9. Regular 
oral risperidone and oral haloperidol were associated with higher delirium symptom 
scores and more extrapyramidal side effects in mild-to-moderate severity delirium 1. 
Haloperidol was associated with shorter overall survival in long-term follow-up 
(secondary outcome). This study has focused clinicians away from using 
antipsychotics to manage delirium, unless patients are a danger to 
themselves/others, or very distressed (frightening hallucinations) and non-
pharmacological management has been ineffective 1 9. If an antipsychotic is required, 
use the lowest effective dose for a short time (Box 2). It is best to use as required 
dosing; use lower doses in frail or older people 1. Patients should be assessed for 
antipsychotic-associated extrapyramidal side effects; the risk is lower with new 
generation antipsychotics. Haloperidol should be avoided in Lewy body dementia or 
Parkinson’s disease due to an increased risk of extrapyramidal side effects.  
 
The other study was a single-centre randomised placebo-controlled trial in end-of-life 
severe delirium and agitation on intravenous haloperidol 10. Patients who were 
administered intravenous lorazepam added to haloperidol had less agitation than 
haloperidol and placebo at eight hours 10.  
 
Caution is needed with benzodiazepines as they can exacerbate delirium. The 
exception is use in alcohol/benzodiazepine withdrawal (reverses the underlying 
cause). In severe delirium where sedation is required, a patient may respond to a 
benzodiazepine (in the lowest effective dose) added in second line with an 
antipsychotic. Further research for the role of medications in delirium management is 
needed. 
 
In summary, delirium is common, distressing, and underdiagnosed. Diagnosis is key, 
with an appropriate search for causes, as it is often reversible. Non-pharmacological 
measures should be optimised. Antipsychotics should be used sparingly but may be 
indicated in severe distress from delirium/hallucinations. Benzodiazepines may be 
required in severe agitated delirium unresponsive to prior measures. For optimal 
care, patient evaluation, investigation and management of reversible delirium 
precipitants (according to goals of care) is important and should include patient and 
family education and support, as well as family input into the decision-making 
process (including the patient whenever possible) 2. 
 Box 2: Recommendations for medications for delirium symptoms 1 2. 
Medications are generally not recommended in most cases. If needed, use the lowest 
effective dose for the shortest possible time to relieve symptoms.  
ANTIPSYCHOTICS: The oral route is preferred; if not possible, then use the subcutaneous 
route (if parenteral preparations are available). Start with lower doses in elderly or frail 
patients. Dose reduction of some antipsychotics may be needed in those with renal and 
hepatic impairment. Antipsychotics do not ‘treat’ delirium per se, but rather the symptoms 
(underlying cause/s needs to be reversed to treat the delirium). 
HALOPERIDOL: If non-pharmacological measures are ineffective and/or the patient has 
distressing hallucinations, then 0.5mg haloperidol is recommended as required orally 
(alternative subcutaneously). Dose can be increased to 1mg and repeated up to hourly if 
needed. If a regular dose is needed, this should be the lowest dose (usually given at night or 
BD). Usual daily maximum: <5mg/24h.  
LEVOMEPROMAZINE (METHOTRIMEPRAZINE): This is sometimes used if haloperidol is 
ineffective. It is more sedating. Starting dose 5-12.5mg orally (alternative subcutaneously) 
up to every 2 hours as required. If a regular dose is needed, this should be the lowest dose 
(usually given at night). Usual daily maximum: 50-100mg. 
NEW GENERATION ANTIPSYCHOTICS: olanzapine (2.5-5mg orally or subcutaneously at 
night; can titrate up to 10mg), quetiapine (25mg orally BD; up to 50-100mg BD) and 
aripiprazole (2.5-5mg daily orally; up to 20mg), may provide symptom relief. Some, such as 
quetiapine, are not available as a parenteral preparation. Risperidone has been shown to be 
ineffective in a recent RCT 9. 
BENZODIAZEPINES: They (e.g. midazolam and lorazepam) are first-line in alcohol or 
benzodiazepine withdrawal. In severely distressed delirious patients, benzodiazepines may 
have a role in addition to antipsychotics for sedation and anxiolysis. They should be used 
with caution as they are deliriogenic and associated with an increased risk of falls. 
Recommended doses: Midazolam 2.5mg subcutaneously up to hourly as required. Usual 
maximum as required dose is 5mg. If repeated doses are needed for refractory agitated 
delirium, can administer via a continuous subcutaneous infusion (usually 10-20mg/day; 
usual maximum 40-60mg/day). Lorazepam 0.5-1mg orally or subcutaneously up to hourly as 
required (up to 2mg maximum). If repeated doses are needed, can use regularly, usual 
effective dose 3-6mg/day. 
Use benzodiazepines with caution in the elderly/frail and those with severe liver disease or 
chronic obstructive airways disease; dose reduction may be needed.  
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